The study, published in Supportive Care in Cancer, drew on the Enhanced EHR-facilitated Cancer Symptom Control trial, known as E2C2, a pragmatic cluster-randomized trial conducted across Mayo Clinic oncology practices. Between March 2019 and January 2023, more than fifty thousand adults with solid and liquid tumors were offered symptom screeners through the electronic health record in connection with their oncology visits. From this cohort, the researchers identified 14,590 patients who had completed at least three symptom assessments within a twelve-month window, a threshold chosen to sharpen the precision of individual trajectory estimates. The six symptoms under scrutiny, abbreviated SPPADE, were sleep disturbance, pain, physical function impairment, anxiety, depression, and energy deficit or fatigue. Each was rated by patients on an eleven-point numeric scale from zero, meaning no symptom, to ten, meaning as bad as one can imagine, capturing the preceding week of experience.

What makes this analysis methodologically distinctive is its data source. Most trajectory studies in oncology rely on panel data, in which research staff assess every participant at predetermined intervals. Such designs are expensive, small, and often restricted to a single cancer type or treatment stage. Here, the researchers instead mined routinely collected clinical data, in which assessments occur at irregular intervals determined by visit schedules and patient willingness to complete optional surveys. Latent class growth analysis, a statistical technique designed to identify unobserved subgroups that follow similar patterns of change over time, proved robust to this irregularity. The models included three growth factors, an intercept, a linear slope, and a quadratic term, allowing for non-linear change, and were fitted with two thousand random starts to ensure stable solutions.

Selecting the optimal number of trajectory classes required a careful balancing act across five fit indices. The Bayesian Information Criterion kept declining as classes were added, offering no clear elbow, so the researchers leaned on entropy, the Lo-Mendell-Rubin likelihood ratio test, average posterior probability, and minimum class size thresholds. Five-class solutions repeatedly produced subgroups smaller than five percent of the sample, undermining their reliability. For four of the seven symptom scores examined, including the composite burden score, the four-class solution won on multiple criteria simultaneously. Even where fit statistics pointed elsewhere, clinical interpretability prevailed: for pain, a three-class solution would have erased the worsening trajectory, which affected nearly nine percent of patients and was judged too clinically important to discard.

The result was a remarkably consistent architecture across all six symptoms. On average, 65.5 percent of patients occupied a low-severity stable trajectory, 15.5 percent a high-severity stable trajectory, 10.7 percent an improving trajectory, and 8.4 percent a worsening trajectory. These proportions held with striking uniformity whether the outcome was pain, anxiety, fatigue, or the composite SPPADE score summing all six symptoms from zero to sixty. The authors interpret this consistency as evidence of common underlying dynamics governing symptom stability and change, suggesting that whatever drives a patient toward persistent suffering or toward recovery operates across symptom types rather than being unique to each one.

Just as consequential is what predicted trajectory membership. Using standardized mean differences to screen for imbalance and then multivariable multinomial logistic regression to isolate independent associations, the researchers found that employment status carried the strongest signal, followed by educational attainment, marital status, metastatic disease, and age. Being employed, married or partnered, better educated, older than sixty-five, and free of metastatic cancer each independently increased the likelihood of following the favorable low-stable course. Conversely, patients who were disabled or unemployed, unpartnered, or living with metastatic disease faced significantly elevated relative risks of high, worsening, or changing symptom trajectories across multiple symptoms. Middle-aged patients between forty and sixty-four showed, for example, a 1.5-fold higher relative risk of a worsening physical function trajectory compared with patients under forty, relative to the low-stable comparator.

Perhaps the most surprising finding was what did not matter. Cancer site, so often the organizing principle of oncology research and care, was generally unrelated to symptom trajectory, with standardized mean differences ranging only from 0.06 to 0.15. The exceptions were instructive: fatigue was less likely to improve across nearly all cancer sites compared with remaining at a low stable level, and persistently poor sleep was less likely at several sites. The authors caution, however, that the predominantly White, well-educated sample limits generalizability, and that the small subgroups of African-American and Hispanic patients, each numbering only 132, showed elevated relative risks across multiple symptoms that demand cautious interpretation and further study in more diverse populations.

The clinical implications are immediate. Oncology practices that already administer patient-reported symptom screeners, as E2C2 did through both in-clinic and remote monthly assessments, possess a continuously updating dataset that can stratify patients without any additional data collection. Patients in the low-stable majority might be spared intensive surveillance and offered self-management resources, freeing clinical capacity for those in the high-stable or worsening groups who need collaborative care interventions. The E2C2 trial itself demonstrated that such interventions work, reducing symptom burden while cutting emergency department visits, hospitalizations, and intensive care admissions. Because single-item numeric rating scales are public domain, responsive to change, and preferred by patients over visual analogue scales, the infrastructure for this kind of stratified care is inexpensive and scalable.

The study also opens a research frontier. The authors propose investigating predictors of improvement among severely symptomatic patients and of worsening among those who start low, tracking treatment-related trajectories through chemotherapy, radiation, and surgery, incorporating laboratory values and medication data, and developing finer markers of cancer stage beyond metastasis. Machine learning approaches that predict future symptom trajectories from prior EHR data are already emerging, and this study provides the validated trajectory framework those models will need to predict against. The researchers are candid about limitations: trajectories began at first screener completion rather than diagnosis, intervention effects could not be disentangled, and the analysis identifies associations rather than validating a prospective prediction model. Still, the temporal logic, with baseline characteristics preceding subsequent trajectories, makes reverse causation unlikely.

For a field that has long treated cancer symptoms as static problems to be assessed at single time points, this study delivers a conceptual shift: symptoms have histories, and those histories follow recognizable patterns. Two-thirds of patients may weather their illness with stable, manageable symptoms, but the one-third who suffer persistently or deteriorate can now be identified earlier, using nothing more than the data their health system already collects. The social gradient embedded in the findings, with employment, education, and partnership shaping symptom outcomes as powerfully as tumor biology, is a reminder that supportive cancer care is not only about the cancer. It is about the whole life that the disease interrupts, and about building systems nimble enough to notice when that life begins to buckle under the weight of unrelieved suffering.

Subject of Research: Longitudinal trajectories of sleep, pain, physical function, anxiety, depression, and fatigue symptoms in patients with cancer identified through electronic health record data

Article Title: Identifying the trajectory of SPPADE symptoms in patients with cancer using electronic health record data

Article References: Identifying the trajectory of SPPADE symptoms in patients with cancer using electronic health record data. (n.d.). https://doi.org/10.1007/s00520-026-11234-4

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11234-4

Keywords: cancer symptoms, symptom trajectories, electronic health records, patient-reported outcomes, latent class growth analysis, SPPADE symptoms, oncology, supportive care, fatigue, pain, health informatics, symptom management

The research team assembled a mixed sample of 955 participants drawn from Iran, combining 143 psychiatric patients who met DSM-5 criteria for somatic symptom and related disorders (SSRD) with 812 individuals from the general population who did not carry that diagnosis. The sample had an average age of 34.2 years, with a standard deviation of 11.5 years, and was 66 percent female. This design deliberately blended a clinically severe group with community participants, allowing the investigators to examine how somatization relates to other forms of psychopathology across a wide spectrum of severity rather than only within a narrow patient population.

Methodologically, the study took what the authors describe as a multidimensional approach. Participants completed a battery of self-report questionnaires covering somatic symptoms, psychological syndromes such as depression and anxiety, and two distinct ways of characterizing personality pathology. The first, criterion-based approach reflects the traditional categorical diagnosis of personality disorder, in which individuals are judged against diagnostic checklists. The second, trait-based approach follows the newer dimensional model, assessing maladaptive personality traits as continuous dimensions. By including both frameworks, the researchers could test whether the answer to their question depended on how personality pathology is defined — a critical check, because the field of personality assessment is currently in transition between these two paradigms.

To reduce the many questionnaire items to interpretable constructs, the team used exploratory factor analysis, a statistical technique that identifies clusters of variables that covary together and can be treated as underlying latent dimensions. This procedure extracted four factors corresponding to somatization, psychological syndromes, criterion-based personality disorder, and maladaptive trait-based personality pathology. In other words, the data themselves organized into the conceptual categories the researchers set out to compare, providing a clean foundation for the predictive analyses that followed.

The heart of the study lay in hierarchical linear regression, a technique that allows researchers to enter predictors in stages and measure how much additional variance each block explains. Here the logic was straightforward but powerful: if somatization were fundamentally a manifestation of personality pathology, then personality measures should explain substantial variance in somatic symptom reporting even after current psychological distress is statistically controlled. Conversely, if somatization is chiefly tied to present distress, the psychological syndromes factor should dominate. The results were unambiguous, and the effect sizes were striking.

Compared with criterion-based personality disorder, the psychological syndromes factor was far more strongly related to the somatization factor. The psychological syndromes accounted for an R-squared of 0.512, meaning they explained just over half of the variance in somatization scores, whereas criterion-based personality pathology explained only 0.105. In the hierarchical models, the incremental contribution — the change in R-squared — was 0.414 for psychological syndromes against a mere 0.007 for criterion-based personality disorder. The same pattern emerged when the trait-based model was used instead: psychological syndromes achieved an R-squared of 0.512 versus 0.138 for maladaptive traits, with incremental values of 0.377 versus 0.004. Whichever lens was applied to personality, the conclusion held.

The team also examined a single-item, pain-related measure as a separate outcome, and here too psychological syndromes outperformed both personality frameworks, though with smaller absolute effects. The syndromes factor explained an R-squared of 0.151 for the pain measure, compared with 0.067 for criterion-based personality disorder and 0.066 for trait-based pathology. The incremental contributions were 0.086 for psychological syndromes against 0.003 and 0.001 for the two personality approaches respectively. The authors are careful to note that these pain findings rest on a single-item indicator and should not be generalized to multidimensional assessments or to chronic pain conditions, where the underlying dynamics may differ considerably.

What do these numbers mean conceptually? The authors conclude that somatization appears to be a phenomenon primarily related to psychological distress rather than to personality pathology, and that this holds regardless of the theoretical context used to define personality problems. This does not mean personality pathology is irrelevant. The study found that both criterion-based and trait-based personality pathology were independently related to somatization, so the association is real. But when current psychological distress is taken into account, personality pathology shrinks to a marginal predictor. In practical terms, a patient’s present levels of depression, anxiety, and related syndromes carry most of the predictive signal for bodily symptom reporting, while personality structure adds only a thin residual layer of explanation.

The clinical implications are significant. Somatization is notoriously difficult to treat, and patients with somatic symptom and related disorders often consume substantial health care resources through repeated investigations and specialist referrals that yield little relief. If the strongest statistical lever for understanding somatization is current psychological distress rather than entrenched personality pathology, then interventions targeting distress — such as treatments for depression and anxiety — may offer the most direct route to reducing the burden of somatic symptoms. The authors explicitly frame their findings as a way to refine theoretical models and improve clinical outcomes by targeting the most impactful constructs, and the variance figures suggest that distress-focused constructs are precisely those impactful targets.

The study also carries methodological lessons for the research community. Because the pattern of results was consistent across both categorical and dimensional conceptualizations of personality pathology, the conclusion is not an artifact of one diagnostic school. The use of factor analysis to establish latent dimensions before regression, and the hierarchical entry of predictors to isolate incremental validity, provide a template for similar comparative questions in psychopathology research. The work was approved by the ethics committee of the Mind GPS Institute of Kermanshah, Iran, conducted in accordance with the Helsinki Declaration, and supported methodologically by that institute without external funding. As with any cross-sectional, self-report study, causal direction cannot be established, and the general-population sample from a single country invites replication elsewhere. Yet the sheer size of the gap — psychological syndromes explaining roughly half the variance in somatization while personality pathology explains a tenth or less — makes this one of the clearer statistical verdicts the field has received on a long-standing debate, and it points clinicians firmly toward treating the distress, not just the personality, when the body speaks for the mind.

Subject of Research: The relative contribution of psychological syndromes and personality pathology to somatization

Article Title: Relative sensitivity of phenotypic personality pathology and psychological syndromes to somatization phenomenon: a multidimensional approach

Article References: Komasi, S., Macina, C., Miettunen, J., Nazari, A., Heydarpour, B., Shams-Alizadeh, N., & Amianto, F. (2026). Relative sensitivity of phenotypic personality pathology and psychological syndromes to somatization phenomenon: a multidimensional approach. Discover Mental Health. https://doi.org/10.1007/s44192-026-00615-0

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00615-0

Keywords: somatization, somatic symptom and related disorders, personality pathology, psychological distress, DSM-5, hierarchical regression, factor analysis, maladaptive traits, pain, psychopathology, mental health, Relative

The study, led by researchers at the Southern University of Science and Technology, began with a deceptively simple observation. When mice received a spinal injection of morphine, the drug rapidly increased phosphorylation, the biochemical switch that activates EphB1 receptors, in both the dorsal root ganglia, clusters of sensory neurons outside the spinal cord, and the spinal cord itself. In the dorsal root ganglia, morphine also raised levels of ephrinB2, the ligand that binds and switches on EphB1. That increase, the researchers showed, depended on the mu-opioid receptor, the very molecule through which morphine produces pain relief. In other words, morphine appears to trigger its own weakening by activating a signaling pathway that sits alongside its primary target.

To test whether EphB1 signaling actually interferes with pain relief, the team administered ephrinB2-Fc, a laboratory reagent that activates EphB1 receptors, directly into the spinal canal of mice. Even at a low dose that did not alter pain sensitivity on its own, the activator significantly blunted the analgesic effect of morphine in both the tail-flick and hot-plate tests, standard measures of pain response in rodents. Crucially, the dampening effect was selective. EphrinB2-Fc interfered with the analgesia produced by DAMGO, a drug that specifically activates mu-opioid receptors, but left untouched the effects of DPDPE and U69593, which act on the delta and kappa opioid receptor subtypes. That selectivity told the researchers that EphB1 signaling is functionally intertwined with the mu-opioid receptor in particular, not with opioid signaling in general.

The next step was to remove EphB1 and see what happened. Using genetic tools, the team created mice lacking EphB1 receptors specifically in neurons that express Vglut2, a marker of excitatory glutamatergic neurons found both in the dorsal root ganglia and in the spinal dorsal horn, the region where pain signals from the body are processed. When these mice received morphine, the analgesic effect was markedly stronger than in normal animals, while baseline pain sensitivity remained unchanged. The enhancement again applied only to DAMGO, reinforcing the link to mu-opioid receptors. The same pattern held in mouse models of disease: in animals with partial sciatic nerve ligation, a model of neuropathic pain, and in animals implanted with lung carcinoma cells in the tibia, a model of bone cancer pain, deleting EphB1 significantly strengthened morphine’s ability to reverse mechanical allodynia and thermal hyperalgesia.

To separate the peripheral and central contributions, the researchers ran parallel experiments. Crossing mice with an inducible Cre driver called Advillin allowed them to delete EphB1 exclusively in dorsal root ganglion neurons, and this too enhanced morphine analgesia. Meanwhile, injecting a Cre-expressing virus directly into the lumbar spinal cord deleted the receptor only in dorsal horn Vglut2-positive neurons, with the same result. Imaging studies supported the anatomical logic: EphB1 and the mu-opioid receptor are co-expressed in small-diameter sensory neurons, on sensory axon terminals, and in excitatory interneurons of the dorsal horn, where roughly thirty percent of Vglut2-positive neurons carried both Ephb1 and Oprm1, the gene encoding the mu-opioid receptor. Inhibitory neurons showed far less overlap.

Electrophysiology then revealed how removing EphB1 changes the behavior of individual neurons. Opioids quiet pain pathways partly by shutting down voltage-gated calcium channels in sensory neurons, which reduces the release of pain-signaling neurotransmitters. In cultured dorsal root ganglion neurons lacking EphB1, DAMGO suppressed calcium influx, measured by calcium imaging, and calcium currents, measured by patch clamp, more powerfully than in control neurons. In spinal cord slices, DAMGO’s inhibition of spontaneous excitatory synaptic currents in dorsal horn Vglut2-positive neurons was deeper without EphB1, and the drug also produced larger outward potassium currents, a hallmark of opioid receptor activation, in those neurons. Every measure pointed the same way: without EphB1, mu-opioid receptors simply work better.

The mechanism behind that improvement turned out to be receptor trafficking. When mu-opioid receptors are phosphorylated at a specific amino acid, serine 375, by enzymes called G protein-coupled receptor kinases, the adaptor protein beta-arrestin is recruited and drags the receptor off the cell surface into the interior of the cell, where it can no longer respond to morphine. The researchers found that activating EphB1 with ephrinB2-Fc pushed mu-opioid receptors out of the membrane and into the cytoplasm of cultured cells, even without any opioid drug present, and amplified the internalization triggered by DAMGO. EphB1 activation also increased phosphorylation of the receptor at serine 375, both in cell culture and in the dorsal root ganglia and spinal cords of living mice. Conversely, deleting EphB1 blunted that phosphorylation in response to DAMGO, including in the neuropathic and cancer pain models.

The missing link was GRK2, one of the G protein-coupled receptor kinases. Co-immunoprecipitation experiments showed that EphB1 receptors physically associate with GRK2 in the dorsal root ganglia and spinal cord, and that all three proteins, EphB1, GRK2, and the mu-opioid receptor, form a complex. GRK2 is heavily expressed in the same nociceptor populations that carry EphB1 and the opioid receptor. When EphB1 was activated, GRK2 became phosphorylated on tyrosine residues, a modification known to boost the enzyme’s catalytic activity, and GRK2 bound more tightly to the mu-opioid receptor. Paroxetine, an antidepressant already approved by the US Food and Drug Administration that happens to be a potent and selective GRK2 inhibitor, completely reversed the EphB1-driven phosphorylation of the opioid receptor at serine 375 and blocked the receptor internalization that followed. That result anchors the entire pathway: EphB1 activates GRK2, GRK2 phosphorylates the mu-opioid receptor, and the receptor disappears from the cell surface.

The implications reach well beyond a single experiment. Because GRK2 helps terminate signaling for hundreds of G protein-coupled receptors, the ephrin-Eph system may turn out to be a broad regulator of GPCR trafficking in many contexts, a possibility the authors flag as an exciting direction for future work. More immediately, the study offers a concrete strategy against opioid tolerance: if blocking EphB1 signaling, or inhibiting GRK2 with drugs such as paroxetine, keeps mu-opioid receptors on the neuronal surface, patients might obtain durable pain relief at lower opioid doses, reducing both escalation and overdose risk. The findings also add to a growing body of evidence that receptor tyrosine kinases, including the insulin receptor and the epidermal growth factor receptor, crosstalk with opioid receptors and shape analgesia, dependence, and reward. Translating the mouse results into the clinic will require much more work, but the identification of a druggable node in the tolerance machinery gives researchers a clear place to start.

Subject of Research: EphB1 receptor regulation of mu-opioid receptor trafficking and morphine antinociception

Article Title: EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization

Article References: EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization. (n.d.). https://doi.org/10.1002/advs.78099

Image Credits: AI Generated

DOI: 10.1002/advs.78099

Keywords: EphB1, morphine, opioid tolerance, mu-opioid receptor, GRK2, receptor internalization, dorsal root ganglion, spinal cord, pain, analgesia, ephrinB2, paroxetine

An umbrella review sits at the very top of the evidence hierarchy. Rather than analyzing individual clinical trials, it systematically collects and critically appraises all of the existing systematic reviews on a topic, effectively auditing the audits. The research team, led by Adrian Kużdżał of the University of Rzeszów in Poland and including Edzard Ernst of the University of Exeter, a longtime and often pointed critic of unsubstantiated complementary therapies, searched eight major databases including PubMed, MEDLINE, Embase, the Cochrane Database of Systematic Reviews, Web of Science, Scopus, PEDro and Epistemonikos. Their search window stretched from January 2000 to December 2025, capturing a quarter century of accumulated review literature on dry needling delivered with or without usual care by a range of healthcare professionals for musculoskeletal or non-musculoskeletal pain and dysfunction in human subjects. Narrative and non-systematic reviews were excluded, and the team strictly followed the PRIOR reporting guidelines for overviews of reviews.

The scale of the enterprise is striking. The researchers identified 75 systematic reviews that met their eligibility criteria, collectively covering 45,032 individual participants. That is an enormous evidence base by any standard, and it reflects just how much clinical and academic energy has been poured into dry needling over the past two decades. Yet the headline numbers tell a story of deep division within that literature. Fifty of the 75 reviews, or 66.6 percent, reported conclusions favoring dry needling. Seventeen reviews, or 22.6 percent, came down on the fence with equivocal conclusions, while eight reviews, or 10.6 percent, reported outright negative conclusions. On the surface, two thirds of the review literature appears to endorse the technique, and it is easy to see how advocates might cite that figure as proof of effectiveness.

But the authors dug one level deeper, and this is where the picture changes dramatically. Using the ROBIS tool, a validated instrument for assessing the risk of bias in systematic reviews, they found that 57 of the 75 reviews, a full 76 percent, demonstrated a high risk of bias across multiple domains. The problems clustered in the most consequential stages of the review process: study selection, where reviewers may cherry-pick which trials to include; data appraisal, where the quality of the underlying trials is judged; and synthesis, where results are pooled and interpreted. In other words, the machinery that is supposed to make systematic reviews trustworthy was itself frequently compromised. A review with high risk of bias in these domains can produce optimistic conclusions that simply do not survive rigorous scrutiny.

The most telling analysis concerns the minority of reviews that passed the quality test. Among the 18 systematic reviews judged to be at low risk of bias, the picture was far less rosy than the raw numbers suggested. Twelve of those 18, or 66.6 percent, still reported favorable conclusions, but five, or 27.7 percent, were equivocal and one, or 5.5 percent, was negative. Even among the best-conducted reviews, a third failed to find clear benefit, and the authors emphasize that the certainty of the evidence underpinning the favorable conclusions remained limited because of high risk of bias in the primary trials and substantial statistical heterogeneity between studies. Heterogeneity, in the language of meta-analysis, means that the pooled effect sizes extracted from the reviews varied widely across conditions, outcome measures and comparison groups, making it difficult to state with confidence what a typical patient should expect.

The umbrella review also examined the degree to which the 75 reviews were recycling the same primary trials, a problem known in evidence synthesis as overlap. When many reviews analyze overlapping pools of studies, the apparent volume of evidence is inflated and the reviews are not independent tests of the hypothesis. The researchers quantified this using the Corrected Covered Area, or CCA, a standard metric for overlap assessment. The result was a CCA of 1.09, which the authors classify as slight overlap. That finding is genuinely reassuring in one respect: the 75 reviews are largely built on different combinations of primary studies rather than repeatedly reanalyzing the same small trial set. The problem, then, is not redundancy but quality, since the sheer breadth of the literature has not translated into methodological rigor.

Safety is where the review delivers perhaps its most practical warning. Dry needling involves penetrating the skin with needles, and like any invasive procedure it carries potential for adverse effects, ranging from common transient soreness and bleeding at the needle site to rarer but more serious events such as pneumothorax when needles are placed near the chest wall. Yet the review found that only 36 of the 75 systematic reviews, or 48 percent, reported any adverse-effect data at all. The remaining 39 reviews, more than half, failed to provide any information on harms. This pattern of underreporting is a well-recognized blind spot in the complementary and manual therapy literature, where enthusiasm for benefit often outpaces systematic attention to risk. Patients and clinicians cannot make genuinely informed decisions when half of the evidence synthesis literature is silent on safety.

Putting all of this together, the authors conclude that no definitive judgments about the clinical effectiveness of dry needling in reducing pain and disability can currently be drawn, and that the existing findings should be interpreted with caution. That is not the same as declaring the technique useless; it is a statement about the state of the evidence. The favorable conclusions reported by many reviews may reflect real effects, but they may equally reflect biased trial design, small samples, unblinded outcome assessment, publication bias and the methodological weaknesses that pervade three quarters of the review literature itself. The authors call for high-quality, condition-specific systematic reviews and randomized clinical trials to resolve the uncertainty, and their work is registered in PROSPERO under identifier CRD420251058215, underscoring the transparency of their own protocol.

For clinicians, the implications are nuanced. Dry needling is often used for conditions such as myofascial pain syndrome, low back pain, tension-type headache, cervicogenic headache and fibromyalgia, and outcome measures in the reviewed literature included familiar instruments such as the Numeric Pain Rating Scale, the Visual Analog Scale, the Neck Disability Index, the Oswestry Disability Index, the Roland-Morris Disability Questionnaire and the WOMAC osteoarthritis index. The umbrella review does not show that the technique harms patients in the conditions studied, and the slight overlap analysis suggests the field has genuinely explored a wide range of clinical questions. But a therapy whose evidence base is dominated by high-risk-of-bias reviews cannot be presented to patients as proven, and the inconsistent safety reporting means that even the risk profile is incompletely mapped.

For the broader public, the study is a masterclass in why the phrase systematic review alone should not end an argument. Seventy-five reviews and forty-five thousand participants sound like overwhelming evidence, yet the umbrella review demonstrates that the architecture of that evidence, not just its quantity, determines what can be believed. The work, funded by the Statutory Research Fund of the Collegium Medicum at the University of Rzeszów with support from the Polish Ministry of Science and Higher Education, and published open access under a Creative Commons license, offers a comprehensive map of where dry needling research stands and where it must go. Until better trials and better reviews arrive, the needles may keep going in, but the verdict on dry needling remains, scientifically speaking, an open question.

Subject of Research: Effectiveness and safety of dry needling for pain and dysfunction, evaluated through an umbrella review of systematic reviews

Article Title: How effective is dry needling? an umbrella review

Article References: Kużdżał, A., Ernst, E., Trybulski, R., & Posadzki, P. (2026). How effective is dry needling? an umbrella review. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05607-9

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05607-9

Keywords: dry needling, umbrella review, systematic review, myofascial trigger points, pain, disability, risk of bias, ROBIS, adverse effects, physical therapy, evidence-based medicine, musculoskeletal conditions

A new cross-sectional study published in Breast Cancer Research and Treatment by researchers at Memorial Sloan Kettering Cancer Center offers a striking clue: it may not be chemotherapy alone, or any single symptom, but the accumulated weight of multiple co-occurring symptoms that shapes how impaired survivors feel. Led by Xiaotong Li and Jun J. Mao, the team analyzed enrollment data from 260 women with stage 0 to III breast cancer who were cancer-free at the time of assessment but reported both moderate or greater cognitive complaints and clinically significant insomnia. Using a novel Cumulative Symptoms Score, or CSS, they quantified the total severity of five common comorbid symptoms, insomnia, fatigue, pain, anxiety, and depression, and asked how this overall burden related to both subjective and objective measures of cognition.

The methodology was deliberately rigorous. Subjective CRCI was measured with the Functional Assessment of Cancer Therapy–Cognitive Function questionnaire, specifically its perceived cognitive impairment subscale, a 37-item self-report instrument with strong internal consistency. Objective cognition was assessed with the Hopkins Verbal Learning Test–Revised, a word-list learning and memory test recommended by the International Cognition and Cancer Task Force, in which participants recall words across repeated trials and again after a 20-to-25-minute delay. Each of the five comorbid symptoms was measured with validated instruments: the Insomnia Severity Index for sleep, the Brief Fatigue Inventory for fatigue, a PROMIS Global Health pain item, and the Hospital Anxiety and Depression Scale for psychological distress. The CSS assigned each symptom a severity score of zero for mild, one for moderate, or two for severe, yielding a total between zero and ten.

The symptom burden in this cohort was extraordinary. Ninety percent of participants reported moderate or severe fatigue, 70 percent had clinically meaningful insomnia, 45 percent reported significant pain, 35 percent reported anxiety, and 11.5 percent reported depression. The authors note these prevalence rates are two to four times higher than those typically observed in the broader breast cancer survivor population, which reflects the study’s focus on patients who actively seek care for sleep and cognitive problems. The mean CSS of 4.6 on the ten-point scale confirmed that these women were carrying, on average, multiple moderate-to-severe symptoms simultaneously, a pattern consistent with the symptom-cluster literature showing that comorbid symptoms rarely occur in isolation.

The central finding is a tale of two cogntions. When the researchers ran multivariable linear regression models adjusting for age and chemotherapy history, each one-point increase in the CSS predicted a roughly three-point drop on the perceived cognitive impairment scale (coefficient -3.0, 95 percent CI -3.6 to -2.4, p < 0.001). Every individual symptom also correlated with subjective impairment, with fatigue, insomnia, and depression showing moderate negative correlations around -0.40. But the CSS showed no significant association with the objective HVLT delayed recall scores (p = 0.58), a null result that persisted after adjusting for age, ethnicity, cancer stage, and even education in sensitivity analyses. Only insomnia correlated with objective performance, showing a weak but significant negative correlation (r = -0.20, p < 0.001).

This dissociation between how impaired survivors feel and how they actually perform on neuropsychological testing is one of the study’s most compelling contributions. Of the 241 participants who completed both assessments, 88.5 percent scored below the clinical cutoff for subjective impairment, yet only 30.3 percent fell below the objective threshold, and just 27 percent met criteria for both. The researchers propose several explanations for this gap. Subjective measures capture the everyday cognitive struggles of real life, whereas structured tests are administered under quiet, optimal conditions that may mask the influence of daily stressors. Many neurocognitive batteries were originally designed to detect dementia-level deficits, leaving survivors with sufficient cognitive reserve to score normally even while experiencing genuine functional difficulties. Moreover, some treatment-related brain changes visible on imaging, such as reduced white matter integrity, appear to recover within three to four years after treatment, while comorbid symptoms often persist far longer.

Perhaps the most provocative implication concerns chemotherapy. Once cumulative symptom burden entered the statistical models, chemotherapy history was no longer associated with subjective cognitive complaints, and hormonal therapy showed no association either. This suggests that what clinicians often attribute to chemo brain may, in this highly symptomatic population, be driven at least in part by the broader load of co-occurring symptoms rather than cytotoxic treatment alone. Interestingly, older age predicted better subjective cognition, which the authors interpret as possibly reflecting younger survivors’ greater work and family demands, and older survivors’ tendency to attribute cognitive lapses to normal aging.

The insomnia finding carries particular mechanistic weight. Sleep is essential for memory consolidation, a process well documented in neuroscientific work showing that sleep-dependent learning depends on the replay and stabilization of new memories during specific sleep stages. Chronic insomnia may additionally contribute to structural brain changes, with neurobiological studies linking poor sleep to reduced gray matter volume and compromised white matter integrity in regions supporting attention, memory, and executive function. In this study, insomnia was the only symptom that bridged the subjective-objective divide, correlating with both how impaired women felt and how they actually performed on memory testing. That makes sleep a uniquely actionable therapeutic target: interventions such as cognitive behavioral therapy for insomnia, which has already shown promise in randomized trials for reducing perceived cognitive impairment in cancer survivors, could potentially improve both the experience and the measurable performance of cognition.

The clinical implications are substantial. The study suggests that CRCI management should move beyond a single-symptom mindset toward multicomponent strategies that address symptom clusters, including exercise interventions for fatigue, pain management, psychological support for anxiety and depression, and sleep-focused therapies. It also offers a sobering note for trial recruitment: researchers hoping to enroll patients with objectively measured CRCI may need to screen roughly three times as many self-reporting patients, given how often subjective complaints occur without measurable deficits. Both types of assessment remain valuable, the authors argue, because they capture different facets of cognitive health influenced by distinct biological and psychological factors.

The researchers acknowledge important limitations. The cross-sectional design cannot establish whether symptom burden causes perceived impairment or whether shared underlying distress drives both, and longitudinal studies are needed to disentangle the direction of these relationships. The cohort was drawn from the enrollment visit of a clinical trial testing acupuncture for insomnia-related CRCI, meaning participants may be more symptomatic than the average survivor, though they represent the patients most likely to seek and benefit from care. The sample was also predominantly White, college-educated, English-speaking, and treated at a well-resourced urban academic center, which limits generalizability. The simple summative CSS may not capture the full complexity of symptom interactions, and only one objective cognitive test was used. Even so, by quantifying the combined weight of five co-occurring symptoms and showing that this cumulative burden tracks with subjective but not objective impairment, the study reframes brain fog not as a mysterious side effect of chemotherapy alone, but as the cognitive signature of a body and mind carrying too many symptoms at once, a reframing that points directly toward treatable targets.

Subject of Research: The association between cumulative comorbid symptom burden and subjective versus objective cognitive impairment in breast cancer survivors

Article Title: Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study

Article References: Li, X., Lampson, K., Liou, K. T., Li, Y., Li, S. Q., Ahles, T., Root, J., & Mao, J. J. (2026). Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study. Breast Cancer Research and Treatment, 219(3), Article 13. https://doi.org/10.1007/s10549-026-08064-7

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08064-7

Keywords: breast cancer, cancer-related cognitive impairment, chemotherapy brain, insomnia, fatigue, symptom burden, survivorship, cognitive function, pain, anxiety, depression, sleep

The review places music intervention within a biopsychosocial model of medicine, which recognizes that cancer affects biological systems as well as emotions, behavior, relationships and daily functioning. A diagnosis can trigger fear and uncertainty, while repeated procedures, treatment toxicity, financial pressure and concerns about recurrence can intensify psychological distress. These experiences can influence sleep, pain perception, treatment participation and recovery. The authors distinguish among music therapy delivered by trained professionals, medical music listening in which healthcare staff provide recorded music, and recreational musical activities led by musicians or clinical personnel. The distinctions matter because the interventions differ in intensity, personalization, therapeutic goals and the expertise required to deliver them.

Evidence summarized in the review suggests that the most consistent benefits occur when music is integrated with clinical assessment and patient preference rather than imposed as a generic soundtrack. During chemotherapy, for example, patients may listen to selected music for about an hour while receiving routine care. In studies of procedures such as peripherally inserted central catheter placement, sessions lasting about 30 minutes were associated with lower anxiety and changes in vital signs, including diastolic blood pressure and heart rate. A randomized study involving 304 people with lung cancer reported benefits when music accompanied routine care during catheter placement and afterward. Research involving children with leukemia similarly linked music therapy during catheter treatment with improved mood, less pain and reduced sedative use, although the review emphasizes that intervention designs and outcomes vary.

Music may also help patients manage the cognitive and emotional burden that accompanies cancer treatment. Chemotherapy-associated cognitive difficulties can involve memory, attention, learning and executive function, and these changes may compound the distress of diagnosis. The review cites a randomized study of 27 breast cancer survivors in which eight weeks of either meditation or classical music listening improved cognitive function, memory and verbal fluency. It also discusses postoperative brain-tumor research in which cognitive training combined with music intervention was associated with better cognitive function, sleep and psychological status. The proposed value of music in these settings is partly communicative: singing, listening, guided imagery or improvisation can give patients a manageable way to express emotions, focus attention and participate actively in their care.

Symptom control is the largest area covered by the review. Anxiety and fear can rise before imaging, surgery, chemotherapy or other procedures, particularly when patients must remain still in an enclosed or noisy environment. Music-guided relaxation before or during a procedure may reduce arousal and help patients complete care. In one study of 750 outpatient chemotherapy patients, participants who selected their own music experienced improvements in negative emotions and pain measures compared with routine care. A separate pilot trial combining face-to-face music listening with progressive muscle relaxation for three weeks reported lower anxiety, depression and stress at the end of treatment, with benefits still evident at follow-up. However, the evidence is not uniform: a meta-analysis of six randomized trials found improvements in anxiety and quality of life before chemotherapy but no substantial effect on depression.

Studies of chemotherapy-induced nausea and vomiting point to a similarly promising but qualified role. Antiemetic drugs remain central to prevention and treatment, yet nausea is influenced by anticipation, anxiety, sensory cues and a patient’s interpretation of symptoms. The review describes a meta-analysis of 10 studies that found music reduced the incidence and severity of anticipated nausea and vomiting, while noting continuing uncertainty about acute symptoms during or immediately after chemotherapy. Other analyses reported lower nausea and vomiting scores and a reduced likelihood of at least grade-one symptoms when individualized music was added to standard nursing care, particularly in gastrointestinal cancer. The findings suggest that timing, musical preference, therapeutic guidance and the patient’s prior experience may all shape the response, making repeated assessment important.

Pain, sleep and fatigue are additional targets. In palliative care, music selected according to patient preference and combined with medication was associated with lower pain and greater comfort in a randomized study of 60 people. After lung-cancer surgery, music therapy alongside intravenous sufentanil analgesia was linked to lower pain scores and reduced dose and administration frequency over the first postoperative day. Music does not act as a substitute for analgesics, but relaxation and attentional engagement may alter how pain is perceived and help patients use other treatments more effectively. Sleep studies have reported benefits after sessions of roughly 30 minutes; a meta-analysis of hospitalized patients found improved sleep quality, and studies in breast and lung cancer suggested additional gains when music was combined with exercise or psychological support.

The review also describes music as a possible bridge between symptom management and physical rehabilitation. After breast-cancer surgery, programs combining music-guided relaxation with limb exercises were associated with improved shoulder movement, reduced swelling and fewer discomfort symptoms. In lung rehabilitation, music can provide rhythm or structure for breathing exercises, relaxation and vocal activities. Evidence from pulmonary rehabilitation, cardiothoracic surgery and postoperative non-small-cell lung cancer care suggests potential improvements in respiratory muscle performance, lung expansion, functional indices and quality of life. These interventions require clinical judgment: therapists must consider cardiovascular and pulmonary function, pain during breathing, the prescribed inhalation-to-exhalation ratio, fatigue and the patient’s preferences. Severe respiratory or cardiovascular problems require coordination with the treating physician.

Combining music with other supportive approaches may produce broader effects than music alone. The review cites studies pairing it with mindfulness-based stress reduction, progressive muscle relaxation, aromatherapy, acupressure and aerobic exercise. In patients with osteosarcoma, music combined with mindfulness practices was associated with improvements in pain, anxiety and sleep. Among women undergoing breast-cancer treatment, aromatherapy plus music relaxation performed better for perioperative pain and anxiety than either intervention alone. Yet the authors caution that many studies are small, use different musical formats and measure short-term outcomes, making direct comparison difficult. Music intervention should therefore be viewed as patient-centered supportive care, not an anticancer treatment or a guaranteed method of changing survival. Larger, rigorously designed trials are needed to establish which patients benefit, which delivery methods work best, how often sessions should occur and whether gains persist. For now, the review argues that music offers a relatively simple, safe and adaptable addition to multidisciplinary oncology care when integrated with medical treatment and individualized assessment.

The clinical rationale for these interventions extends beyond distraction. Within the biopsychosocial framework described by the review, music can engage emotional, cognitive and social dimensions of illness at the same time. It may provide a familiar structure during periods in which diagnosis and treatment feel unpredictable, while also creating an avenue for communication when patients find direct discussion difficult. In a therapeutic setting, a patient’s responses to a song, rhythm or musical activity can help reveal distress, preferences and changing needs. This makes music potentially relevant not only to symptom relief but also to the human relationship at the center of supportive oncology.

Delivery should be matched to the purpose of care. Passive listening may be practical in an infusion unit, before a procedure or during rest, whereas music therapy involves a qualified practitioner who adapts the session and uses music within a defined treatment process. Active approaches, such as singing or other guided musical participation, may encourage agency and interaction, but they are not interchangeable with recorded music. The review’s comparison of studies found more consistently favorable findings for interventions provided by trained music therapists, while results for medical music listening were less uniform. This distinction is important when hospitals interpret evidence or plan services.

Patient choice is another clinically meaningful variable. Musical familiarity, cultural background, age, language, prior experiences and current mood can influence whether a session feels calming, irritating or emotionally overwhelming. The review therefore supports flexible strategies rather than a single preferred genre or universal protocol. Clinicians can ask what the patient normally listens to, whether music is welcome at that moment and whether listening should be uninterrupted or combined with conversation, breathing practice or rehabilitation. Patients should also be able to stop an intervention, particularly when music evokes unwanted memories or increases discomfort.

Implementation is best understood as part of coordinated supportive care rather than an isolated activity. Oncology nurses, physicians, rehabilitation professionals, palliative-care teams and music therapists may use different observations to determine whether a session is helping. Repeated assessment can include the patient’s reported anxiety, pain, nausea, sleep or fatigue, together with participation in treatment and functional recovery. Such monitoring can identify when music is useful and when another intervention is needed. It also helps separate immediate comfort from longer-term outcomes, a necessary distinction because the reviewed studies varied in intervention length, cancer type, setting and outcome measurement.

The review’s findings support continued clinical investigation, but they do not establish that music directly alters tumor biology or reliably extends survival. Most of the evidence concerns patient-reported symptoms, psychological states, physiological responses or rehabilitation measures. Future studies would benefit from clearer descriptions of therapist training, session content, timing, dose, patient selection and usual-care comparisons. Consistent outcome measures and longer follow-up could clarify whether short-term reductions in distress translate into sustained improvements in functioning, adherence or quality of life. Until then, music is most appropriately offered as an individualized, low-burden complement to evidence-based cancer treatment and palliative care.

Subject of Research: Clinical use of music interventions to support psychological, physical and rehabilitation outcomes in cancer patients

Article Title: The integrated application of music intervention in clinical practice for cancer patients

Article References: Zhang, F., Li, X., Wang, J., Ma, M., Xu, Y., & Hong, L. (2026). The integrated application of music intervention in clinical practice for cancer patients. Holistic Integrative Oncology, 5(1), Article 71. https://doi.org/10.1007/s44178-026-00271-y

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00271-y

Keywords: music therapy, cancer care, integrative oncology, symptom management, anxiety, pain, sleep, chemotherapy, rehabilitation, quality of life, integrated, application